[go: up one dir, main page]

HK1209750A1 - Thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them - Google Patents

Thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them Download PDF

Info

Publication number
HK1209750A1
HK1209750A1 HK15110667.4A HK15110667A HK1209750A1 HK 1209750 A1 HK1209750 A1 HK 1209750A1 HK 15110667 A HK15110667 A HK 15110667A HK 1209750 A1 HK1209750 A1 HK 1209750A1
Authority
HK
Hong Kong
Prior art keywords
phenyl
pyrimidin
chloro
methyl
thieno
Prior art date
Application number
HK15110667.4A
Other languages
English (en)
Chinese (zh)
Inventor
András Kotschy
Zoltán SZLÁVIK
Márton Csékei
Attila Paczal
Zoltán SZABÓ
Szabolcs SIPOS
Gábor Radics
Ágnes Proszenyák
Balázs Bálint
Alain Bruno
Olivier Geneste
James Edward Paul Davidson
James Brooke MURRAY
I-Jen Chen
Françoise PERRON-SIERRA
Original Assignee
Les Laboratoires Servier
VERNALIS (R&D) Limited.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Servier, VERNALIS (R&D) Limited. filed Critical Les Laboratoires Servier
Publication of HK1209750A1 publication Critical patent/HK1209750A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HK15110667.4A 2013-12-23 2015-10-28 Thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them HK1209750A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1363500A FR3015483B1 (fr) 2013-12-23 2013-12-23 Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR1363500 2013-12-23

Publications (1)

Publication Number Publication Date
HK1209750A1 true HK1209750A1 (en) 2016-04-08

Family

ID=50829005

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15110667.4A HK1209750A1 (en) 2013-12-23 2015-10-28 Thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them

Country Status (48)

Country Link
US (3) US9670227B2 (fr)
EP (1) EP2886545B1 (fr)
JP (1) JP5922215B2 (fr)
KR (1) KR101636401B1 (fr)
CN (1) CN104725397B (fr)
AP (1) AP2014008127A0 (fr)
AR (1) AR098906A1 (fr)
AU (1) AU2014274644B2 (fr)
BR (1) BR102014032336B1 (fr)
CA (1) CA2875226C (fr)
CL (1) CL2014003444A1 (fr)
CO (1) CO7210068A1 (fr)
CR (1) CR20140569A (fr)
CU (1) CU24309B1 (fr)
CY (1) CY1118058T1 (fr)
DK (1) DK2886545T3 (fr)
DO (1) DOP2014000282A (fr)
EA (1) EA029601B1 (fr)
ES (1) ES2594377T3 (fr)
FR (1) FR3015483B1 (fr)
GE (1) GEP201706619B (fr)
GT (1) GT201400297A (fr)
HK (1) HK1209750A1 (fr)
HR (1) HRP20161203T8 (fr)
HU (1) HUE029654T2 (fr)
IL (1) IL236143A (fr)
JO (1) JO3193B1 (fr)
LT (1) LT2886545T (fr)
MD (1) MD4516C1 (fr)
ME (1) ME02521B (fr)
MX (1) MX351581B (fr)
MY (1) MY185221A (fr)
NI (1) NI201400150A (fr)
PE (1) PE20151064A1 (fr)
PH (1) PH12014000375B1 (fr)
PL (1) PL2886545T3 (fr)
PT (1) PT2886545T (fr)
RS (1) RS55213B1 (fr)
RU (1) RU2605403C2 (fr)
SA (1) SA114360144B1 (fr)
SG (1) SG10201408563UA (fr)
SI (1) SI2886545T1 (fr)
TN (1) TN2014000516A1 (fr)
TW (1) TWI508969B (fr)
UA (1) UA120341C2 (fr)
UY (1) UY35915A (fr)
WO (1) WO2015097123A1 (fr)
ZA (1) ZA201409365B (fr)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2803581T3 (es) 2014-10-29 2021-01-28 Walter & Eliza Hall Inst Medical Res Inhibidores de Mcl-1 para su uso en el tratamiento de enfermedades provocadas por neovascularización patológica
HK1257555A1 (zh) * 2015-05-27 2019-10-25 Gb005, Inc. Tec激酶家族之抑制剂
FR3037958B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037959B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037957B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037956B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3046792B1 (fr) * 2016-01-19 2018-02-02 Les Laboratoires Servier Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP3454862B1 (fr) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Dégronimères spirocycliques pour la dégradation de protéines cibles
WO2017197055A1 (fr) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Dégronimères hétérocycliques pour la dégradation de protéines cibles
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
UA125138C2 (uk) * 2016-07-22 2022-01-19 Ле Лаборатуар Сервьє Комбінація інгібітора bcl-2 та інгібітора mcl-1, їхнє застосування і фармацевтичні композиції
WO2018015526A1 (fr) 2016-07-22 2018-01-25 Les Laboratoires Servier Combinaison d'un inhibiteur de bcl-2 et d'un inhibiteur de mcl-1, utilisations et compositions pharmaceutiques associées
LT3532067T (lt) * 2016-10-28 2022-08-25 Les Laboratoires Servier Liposominė vaisto forma, skirta naudoti gydant vėžį
EP3567043B1 (fr) * 2017-01-05 2023-12-06 Henan Genuine Biotech Co., Ltd. Dérivés du acide propanoïque 2-[[5-[(4-hydroxy-3-chloro-2-méthyl)-phényl]-thiéno[2,3-d]pyrimidin-4-yl]oxy]-3-(2-méthoxybenzene) en tant qu'inhibiteurs mcl-1 et bcl-2 pour le traitement du cancer
UY37560A (es) 2017-01-06 2018-07-31 Servier Lab Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta
CA3049095C (fr) * 2017-01-06 2022-01-25 Les Laboratoires Servier Combinaison d'un inhibiteur de mcl-1 et d'un compose de taxane, ses utilisations et compositions pharmaceutiques la comprenant
EA039621B1 (ru) * 2017-06-09 2022-02-17 Ле Лаборатуар Сервье Комбинация bcl-2 ингибитора и mcl-1 ингибитора, их применения и фармацевтические композиции
CN110769822A (zh) 2017-06-20 2020-02-07 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
JP7186731B2 (ja) * 2017-06-22 2022-12-09 レ ラボラトワール セルヴィエ 血液ガンのためのｍｃｌ－１阻害剤と標準治療処置との組み合わせ、その使用及び医薬組成物
GB201712282D0 (en) 2017-07-31 2017-09-13 Nodthera Ltd Selective inhibitors of NLRP3 inflammasome
EP3652184A4 (fr) * 2017-08-15 2020-05-20 AbbVie Inc. Inhibiteurs macrocycliques de mcl-1 et méthodes d'utilisation
WO2019035927A1 (fr) * 2017-08-15 2019-02-21 Abbvie Inc. Inhibiteurs de mcl-1 macrocyclique et procédés d'utilisation
CA3073113A1 (fr) * 2017-08-15 2019-02-21 Abbvie Inc. Inhibiteurs de mcl-1 macrocyclique et procedes d'utilisation
CN107573360B (zh) * 2017-10-27 2019-08-09 都创(上海)医药科技有限公司 一种多靶点小分子化合物s63845的制备方法
CN111372936B (zh) * 2017-11-23 2022-12-02 北京赛林泰医药技术有限公司 Mcl-1选择性抑制剂及其制备和用途
CN108424417B (zh) * 2017-12-21 2019-09-20 河南真实生物科技有限公司 噻吩并嘧啶衍生物、其制备方法及在制备抗肿瘤药物中的应用
CN110964034B (zh) * 2018-09-29 2022-04-12 江苏恒瑞医药股份有限公司 嘧啶并噻吩类衍生物、其制备方法及其在医药上的应用
AR116635A1 (es) * 2018-10-15 2021-05-26 Servier Lab Proceso para la síntesis de derivados de piperazinil-etoxi-bromofenilo y su aplicación en la producción de compuestos que los contienen
TWI849001B (zh) 2018-11-14 2024-07-21 法商施維雅藥廠 Mcl-1抑制劑及米哚妥林(midostaurin)之組合，其用途及醫藥組合物
CN111187277B (zh) * 2018-11-14 2022-04-12 江苏恒瑞医药股份有限公司 噻吩并嘧啶类衍生物、其制备方法及其在医药上的应用
US12129261B2 (en) * 2018-12-06 2024-10-29 Les Laboratoires Servier Crystalline forms of a MCL-1 inhibitor, a process for their preparation and pharmaceutical compositions containing them
CN120698985A (zh) 2018-12-20 2025-09-26 C4医药公司 靶向蛋白降解
US20230092679A1 (en) 2019-05-20 2023-03-23 Novartis Ag Mcl-1 inhibitor antibody-drug conjugates and methods of use
AR119156A1 (es) 2019-06-17 2021-11-24 Servier Lab Combinación de un inhibidor de mcl-1 y un tratamiento estándar de atención médica para cáncer de mama, usos y composiciones farmacéuticas de la misma
AR119494A1 (es) 2019-07-29 2021-12-22 Servier Lab DERIVADOS DE 6,7-DIHIDRO-5H-PIRIDO[2,3-c]PIRIDAZIN-8-ILO, COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y SUS USOS COMO AGENTES PROAPOPTÓTICOS
AR119493A1 (es) 2019-07-29 2021-12-22 Servier Lab Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmacéuticas que los contienen y sus usos como agentes proapoptóticos
US20230116602A1 (en) * 2019-10-03 2023-04-13 California Institute Of Technology Mcl1 inhibitors and uses thereof
CN113024578A (zh) * 2019-12-09 2021-06-25 首药控股(北京)有限公司 一种mcl1选择性抑制剂的多晶型物及其制备方法
CN113024577B (zh) * 2019-12-09 2023-06-30 首药控股(北京)股份有限公司 一种抗凋亡蛋白选择性抑制剂的制备方法
WO2022090443A1 (fr) 2020-10-30 2022-05-05 Les Laboratoires Servier Administration et posologie pour une combinaison d'un inhibiteur de bcl-2 et d'un inhibiteur de mcl-1
US20240042051A1 (en) 2020-11-24 2024-02-08 Francesca Rocchetti Mcl-1 inhibitor antibody-drug conjugates and methods of use
CN116761635A (zh) 2020-11-24 2023-09-15 诺华股份有限公司 Bcl-xl抑制剂抗体药物缀合物及其使用方法
UY39609A (es) 2021-01-12 2022-08-31 Servier Lab Nuevos derivados de espirociclohexano, composiciones farmacéuticas que los contienen y sus usos como inhibidores antiapoptóticos
CN117794929A (zh) 2021-02-02 2024-03-29 法国施维雅药厂 选择性bcl-xl protac化合物及使用方法
WO2022216946A1 (fr) * 2021-04-07 2022-10-13 California Institute Of Technology Inhibiteurs de mcl1 et leurs utilisations
WO2022255888A1 (fr) * 2021-06-01 2022-12-08 Captor Therapeutics S.A. Dégradation de protéine ciblée à l'aide de composés bifonctionnels qui se lient à l'ubiquitine ligase et à la protéine mcl-1 cible
WO2022261310A1 (fr) 2021-06-11 2022-12-15 Gilead Sciences, Inc. Inhibiteurs de mcl-1 en combinaison avec des conjugués anti-corps-médicament
EP4351564A1 (fr) 2021-06-11 2024-04-17 Gilead Sciences, Inc. Inhibiteurs de mcl-1 en combinaison avec des agents anticancéreux
KR20250027281A (ko) 2022-05-20 2025-02-25 노파르티스 아게 Epha2 bcl-xl 억제제 항체-약물 접합체 및 그의 사용 방법
WO2023225359A1 (fr) 2022-05-20 2023-11-23 Novartis Ag Conjugués anticorps-médicament de composés anti-cancéreux et procédés d'utilisation
AU2023273734A1 (en) 2022-05-20 2024-12-12 Les Laboratoires Servier Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
MA71381A (fr) 2022-07-08 2025-04-30 Les Laboratoires Servier Nouveaux dérivés de spirocyclohexane, compositions pharmaceutiques les contenant et leurs utilisations comme inhibiteurs anti-apoptotiques
WO2025111431A1 (fr) 2023-11-22 2025-05-30 Les Laboratoires Servier Conjugués anticorps-médicament anti-cd7 et leurs procédés d'utilisation
WO2025111450A1 (fr) 2023-11-22 2025-05-30 Les Laboratoires Servier Conjugués anticorps anti-cd74-médicament et leurs procédés d'utilisation
WO2025126157A1 (fr) 2023-12-15 2025-06-19 Advesya Domaines de liaison anti-il-1rap et conjugués anticorps-médicament associés

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4008726A1 (de) * 1990-03-19 1991-09-26 Basf Ag Thieno(2,3-d)pyrimidinderivate
PL1641803T6 (pl) * 2003-06-11 2011-04-29 Xention Ltd Pochodne tienopirymidyny jako inhibitory kanału potasowego
WO2005069865A2 (fr) 2004-01-13 2005-08-04 Ambit Biosciences Corporation Derives de pyrrolopyrimidine et analogues et utilisation dans le traitement et la prevention de maladies
US20050288906A1 (en) 2004-06-29 2005-12-29 Drennen James K Iii Spectroscopic pharmacy verification and inspection system
EP1768986A2 (fr) 2004-06-29 2007-04-04 Amgen Inc. Furanopyrimidines
ATE485300T1 (de) * 2004-07-16 2010-11-15 Sunesis Pharmaceuticals Inc Als aurora-kinase-inhibitoren nutzbare thienopyrimidine
GB0423653D0 (en) * 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
US7576080B2 (en) * 2004-12-23 2009-08-18 Memory Pharmaceuticals Corporation Certain thienopyrimidine derivatives as phosphodiesterase 10 inhibitors
WO2007046809A1 (fr) * 2005-10-21 2007-04-26 Dow Agrosciences Llc Composes de thieno-pyrimidine a activite fongicide
ES2571028T3 (es) * 2006-12-07 2016-05-23 Genentech Inc Compuestos inhibidores de fosfoinositida 3-cinasa y métodos de uso
DE102007027800A1 (de) 2007-06-16 2008-12-18 Bayer Healthcare Ag Substituierte bicyclische Heteroaryl-Verbindungen und ihre Verwendung
WO2009052145A1 (fr) * 2007-10-16 2009-04-23 Wyeth Composés thiénopyrimidine et pyrazolopyrimidine et leur utilisation en tant que des inhibiteurs de la kinase mtor et de la kinase pi3
KR101703941B1 (ko) 2008-11-10 2017-02-07 내셔날 헬스 리서치 인스티튜트 티로신 키나아제 억제제로서의 접합 이환 및 삼환 피리미딘 화합물
BR112012033253A2 (pt) * 2010-06-23 2016-11-22 Hanmi Science Co Ltd novos derivados de pirimidina fundidos para inibição da atividade de tirosina quinase
WO2012044993A1 (fr) * 2010-09-30 2012-04-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Composés, compositions pharmaceutiques, et procédés de traitement ou de prévention de maladies ou de troubles neurodégénératifs
CN102464667B (zh) * 2010-11-03 2014-06-04 中国科学院上海药物研究所 一类五元杂环并嘧啶类化合物及其制备方法和用途
AR090037A1 (es) * 2011-11-15 2014-10-15 Xention Ltd Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio
FR2986002B1 (fr) * 2012-01-24 2014-02-21 Servier Lab Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
US9670227B2 (en) 2017-06-06
FR3015483A1 (fr) 2015-06-26
HK1211583A1 (en) 2016-05-27
JP2015129120A (ja) 2015-07-16
AP2014008127A0 (en) 2014-12-31
TN2014000516A1 (en) 2016-03-30
SG10201408563UA (en) 2015-07-30
NZ702851A (en) 2016-05-27
TW201529583A (zh) 2015-08-01
LT2886545T (lt) 2016-09-26
CN104725397B (zh) 2017-11-28
GEP201706619B (en) 2017-02-10
MX351581B (es) 2017-10-20
BR102014032336A2 (pt) 2016-06-07
GT201400297A (es) 2017-08-24
HUE029654T2 (en) 2017-02-28
BR102014032336B1 (pt) 2020-10-20
US20190201404A1 (en) 2019-07-04
FR3015483B1 (fr) 2016-01-01
JP5922215B2 (ja) 2016-05-24
MD20140137A2 (ro) 2015-06-30
RU2605403C2 (ru) 2016-12-20
SA114360144B1 (ar) 2015-10-08
CY1118058T1 (el) 2017-06-28
KR101636401B1 (ko) 2016-07-05
CU20140143A7 (es) 2016-07-29
ZA201409365B (en) 2021-07-28
US20150175623A1 (en) 2015-06-25
PH12014000375B1 (en) 2017-10-11
CA2875226C (fr) 2018-03-13
CN104725397A (zh) 2015-06-24
JO3193B1 (ar) 2018-03-08
EP2886545B1 (fr) 2016-06-29
EA201401292A2 (ru) 2015-06-30
MD4516C1 (ro) 2018-04-30
RS55213B1 (sr) 2017-02-28
HRP20161203T1 (hr) 2016-11-04
US20170216293A1 (en) 2017-08-03
MY185221A (en) 2021-04-30
DK2886545T3 (en) 2016-09-19
CR20140569A (es) 2016-07-01
UA120341C2 (uk) 2019-11-25
MX2014015854A (es) 2015-07-22
CO7210068A1 (es) 2015-03-09
WO2015097123A1 (fr) 2015-07-02
AU2014274644A1 (en) 2015-07-09
CA2875226A1 (fr) 2015-06-23
PH12014000375A1 (en) 2016-06-13
EP2886545A1 (fr) 2015-06-24
KR20150073874A (ko) 2015-07-01
PT2886545T (pt) 2016-08-25
SI2886545T1 (sl) 2016-10-28
CL2014003444A1 (es) 2015-10-23
ES2594377T3 (es) 2016-12-19
RU2014151850A (ru) 2016-07-20
PE20151064A1 (es) 2015-08-08
ME02521B (fr) 2017-02-20
CU24309B1 (es) 2018-01-10
HRP20161203T8 (hr) 2016-12-30
MD4516B1 (ro) 2017-09-30
AU2014274644B2 (en) 2019-11-14
AR098906A1 (es) 2016-06-22
US10278972B2 (en) 2019-05-07
DOP2014000282A (es) 2016-06-30
EA201401292A3 (ru) 2015-08-31
PL2886545T3 (pl) 2017-03-31
NI201400150A (es) 2015-06-05
TWI508969B (zh) 2015-11-21
UY35915A (es) 2015-07-31
EA029601B1 (ru) 2018-04-30
IL236143A (en) 2017-02-28

Similar Documents

Publication Publication Date Title
TWI508969B (zh) 新噻吩并嘧啶衍生物、其製備方法及包含其之醫藥組合物
DK2958910T3 (en) Pyrimidine compounds which can be used for treating diseases which are mediated by non and / or mechanisms TBK1
CN101356159A (zh) 经取代异喹啉-1,3(2h,4h)-二酮类、1-硫代-1,4-二氢-2h-异喹啉-3-酮类和1,4-二氢-3(2h)-异喹啉酮类以及其作为激酶抑制剂的用途
MX2007014261A (es) Inhibidores de 3-cianoquinolina de cinasa tpl2 y metodos de elaboracion y uso de los mismos.
CN113105475B (zh) 布鲁顿氏酪氨酸激酶的抑制剂及其使用方法
KR20180019223A (ko) 신규한 하이드록시에스테르 유도체, 이들의 제조 방법 및 이들을 함유하는 약학적 조성물
TW201706248A (zh) Ａｐｊ受體之三唑激動劑
EA018945B1 (ru) Производные азакарболинов, способ их получения и применение в терапии
CN102471310A (zh) 用于治疗增生性疾病的联吡啶化合物
EA015574B1 (ru) Триазолиламинопиримидиновые соединения
OA17193A (en) New thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them.
HK1211583B (en) New thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them
HK40076948B (zh) Kras g12d抑制剂
OA17201A (en) Tris(hetero)arylpyrazoles and use thereof.
HK1211922A1 (en) Pyrazolyl quinoxaline kinase inhibitors
HK1211922B (en) Pyrazolyl quinoxaline kinase inhibitors